251 related articles for article (PubMed ID: 22848381)
1. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.
Liu Z; Zhang B; Liu K; Ding Z; Hu X
PLoS One; 2012; 7(7):e40480. PubMed ID: 22848381
[TBL] [Abstract][Full Text] [Related]
2. Schisandrin B inhibits TGF-β1-induced epithelial-mesenchymal transition in human A549 cells through epigenetic silencing of ZEB1.
Zhuang W; Li Z; Dong X; Zhao N; Liu Y; Wang C; Chen J
Exp Lung Res; 2019; 45(5-6):157-166. PubMed ID: 31268360
[No Abstract] [Full Text] [Related]
3. Inhibiting cancer metastasis via targeting NAPDH oxidase 4.
Zhang B; Liu Z; Hu X
Biochem Pharmacol; 2013 Jul; 86(2):253-66. PubMed ID: 23688500
[TBL] [Abstract][Full Text] [Related]
4. Schisandrin B suppresses osteosarcoma lung metastasis
Wang Y; Chen J; Huang Y; Yang S; Tan T; Wang N; Zhang J; Ye C; Wei M; Luo J; Luo X
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029287
[TBL] [Abstract][Full Text] [Related]
5. Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.
Xu Y; Liu Z; Sun J; Pan Q; Sun F; Yan Z; Hu X
PLoS One; 2011; 6(12):e28335. PubMed ID: 22164272
[TBL] [Abstract][Full Text] [Related]
6. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin B inhibits epithelial‑mesenchymal transition and stemness of large‑cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF‑κB and p38 MAPK signaling pathways.
Li S; Wang H; Ma R; Wang L
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907830
[TBL] [Abstract][Full Text] [Related]
8. Schizandrin inhibits fibrosis and epithelial-mesenchymal transition in transforming growth factor-β1-stimulated AML12 cells.
Park JH; Yoon J
Int Immunopharmacol; 2015 Apr; 25(2):276-84. PubMed ID: 25701504
[TBL] [Abstract][Full Text] [Related]
9. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
10. Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.
Yang X; Wang S; Mu Y; Zheng Y
Oncol Rep; 2016 Oct; 36(4):1799-806. PubMed ID: 27499090
[TBL] [Abstract][Full Text] [Related]
11. PEG-GO@XN nanocomposite suppresses breast cancer metastasis via inhibition of mitochondrial oxidative phosphorylation and blockade of epithelial-to-mesenchymal transition.
Zhang J; Yan L; Wei P; Zhou R; Hua C; Xiao M; Tu Y; Gu Z; Wei T
Eur J Pharmacol; 2021 Mar; 895():173866. PubMed ID: 33454376
[TBL] [Abstract][Full Text] [Related]
12. Arenobufagin, isolated from toad venom, inhibited epithelial-to-mesenchymal transition and suppressed migration and invasion of lung cancer cells via targeting IKKβ/NFκB signal cascade.
Zhao J; Zhang Q; Zou G; Gao G; Yue Q
J Ethnopharmacol; 2020 Mar; 250():112492. PubMed ID: 31866511
[TBL] [Abstract][Full Text] [Related]
13. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
14. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
[TBL] [Abstract][Full Text] [Related]
16. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
18. Schisandrin B attenuates renal fibrosis via miR-30e-mediated inhibition of EMT.
Cao G; Li S; Shi H; Yin P; Chen J; Li H; Zhong Y; Diao LT; Du B
Toxicol Appl Pharmacol; 2019 Dec; 385():114769. PubMed ID: 31697999
[TBL] [Abstract][Full Text] [Related]
19. Taxifolin inhibits breast cancer cells proliferation, migration and invasion by promoting mesenchymal to epithelial transition via β-catenin signaling.
Li J; Hu L; Zhou T; Gong X; Jiang R; Li H; Kuang G; Wan J; Li H
Life Sci; 2019 Sep; 232():116617. PubMed ID: 31260685
[TBL] [Abstract][Full Text] [Related]
20. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the wingless/integrase-1 signaling pathway.
Wang Y; Dong X; Zhao N; Su X; Wang Y; Li Y; Wen M; Li Z; Wang C; Chen J; Zhuang W
Exp Lung Res; 2020; 46(6):185-194. PubMed ID: 32362157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
